News and Trends 2 Nov 2022 Authorization given to BeiGene’s chemo-free treatment option for lymphoma Marketing authorization has been granted to a drug to treat relapsed/refractory (R/R) marginal zone lymphoma (MZL) without chemotherapy, it was announced today (November 2). The European Commission (EC) gave the authorization to biotech company, BeiGene, for Brukinsa (zanubrutinib), which treats adults with the condition who have received at least one prior anti-CD20-based therapy. The approval […] November 2, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
Startup Scout 2 Nov 2022 Breakpoint Therapeutics sabotages DNA repair in cancer cells The Hamburg-based Evotec spinout Breakpoint Therapeutics is working on cancer treatments that block the ability of tumor cells to repair their own DNA. In the last decade, a new class of drugs known as DNA damage response (DDR) inhibitors has risen to prominence in the oncology space. These drugs are able to break down the […] November 2, 2022 - 4 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 2 Nov 2022 CV6 Therapeutics raises $9.2M to test cancer drug CV6 Therapeutics has secured $9.2m to progress its lead oncology asset, CV6-168, into a first-in-human phase 1a clinical trial and perform further scientific development work. CV6 Therapeutics is a drug development biotechnology company specializing in innovative small molecule therapeutics for cancer and inflammatory diseases. Investors participating in the financing include QUBIS, the commercialization arm of […] November 2, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 2 Nov 2022 Alkermes to separate oncology business Alkermes plc is to explore separating its commercial-stage neuroscience business and development-stage oncology business. The company, its board and external financial and legal advisors plan to explore a separation of the oncology business into an independent, publicly-traded company (Oncology Co.) as part of an ongoing review of strategic alternatives for the oncology business. Alkermes said […] November 2, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 2 Nov 2022 New therapeutic strategy to improve treatment of aggressive endometrial cancer Endometrial cancer (EC) is the most common type of gynecological cancer and is the fourth most common type of tumor in women in developed countries. Although it has a good prognosis if detected early, advanced and aggressive cases have a high mortality rate and are often resistant to standard chemotherapy treatments. Now, a study published […] November 2, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 2 Nov 2022 Could DNA nanotransporters treat cancer? A team of Canadian researchers from Université de Montréal has designed and validated a new class of drug transporters made of DNA 20,000 times smaller than a human hair. The DNA nanotransporters could improve how cancers and other diseases are treated. Reported in a new study in Nature Communications, the molecular transporters can be chemically […] November 2, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
In Depth 1 Nov 2022 The biggest private biotech investments in October 2022 The companies Tempus Labs, Oculis and VectorBuilder Biotechnology bagged the biggest biotech investments in October 2022. Oncology and biomanufacturing research attracted the biggest funding rounds. We’re heading for the beginning of winter in the Northern Hemisphere, and biotech fundraising is still ticking away despite adverse market conditions. We’ve gathered the biggest biotech investments that went […] November 1, 2022 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 1 Nov 2022 First to market doesn’t guarantee success A comparison of two cancer drugs, Opdivo and Keytruda, reveals that being the first-to-market is not necessarily the main factor in a drug’s success. For the first four years since their approval, the anticancer drug Opdivo outperformed Keytruda in sales. But this trend reversed in 2018, with Keytruda’s sales becoming higher than Opdivo’s. Recently, a […] November 1, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 1 Nov 2022 Pancreatic cancer could be diagnosed years earlier Pancreatic cancer could be identified in patients up to three years earlier than current diagnoses, new research from the U.K. shows. Weight loss and increasing blood glucose levels are early indicators of pancreatic cancer and could lead to a more timely diagnosis, helping to improve survival rates. In the largest study of its kind, researchers […] November 1, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 31 Oct 2022 First patient enrolled and dosed on expansion phase of cancer treatment trial The first patient in an expansion phase of a trial looking at cancer drug Modi-1 has been enrolled and dosed. Scancell Holdings plc, the developer of immunotherapies for the treatment of cancer and infectious disease made the announcement today (October 31). The expansion phase is part of the monotherapy arms of the phase 1 clinical […] October 31, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 31 Oct 2022 Researchers develop efficient nanovaccine delivery system boosting cellular immunity A research group has successfully developed a new nanovaccine delivery system, to strongly activate cellular immunity, using one-tenth of the amount of antigen that was previously required. Led by Eiji Yuba, an associate professor at the Graduate School of Engineering at Osaka Metropolitan University in Japan, the group has been developing been developing the […] October 31, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 31 Oct 2022 Scientists say RNA production inhibitors important in cancer research A study by researchers at the Biomedical Institute of Seville (IBIS) and the University of Seville, in collaboration with the Danish Cancer Society, shows that inhibiting RNA synthesis after radiation therapy facilitates the death of tumor cells. The study was published in the journal Nature Communications. RNA has been shown to be essential for repairing […] October 31, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email